Ocular Surface Journal

Overview
Identity
View All

publication venue for

Clinical practice patterns in the management of dry eye disease: A TFOS international survey 2023-4.. S1542-0124(24)00143-5. 2024
AZR-MD-001 0.5% selenium sulfide ophthalmic ointment for the treatment of contact lens discomfort: A vehicle-controlled, randomized, clinical trial.. S1542-0124(24)00144-7. 2024
Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction over six months of treatment: A Phase 2, vehicle-controlled, randomized extension trial.. 35:15-24. 2024
TFOS Lifestyle Report Executive Summary: A Lifestyle Epidemic - Ocular Surface Disease. 30:240-253. 2023
TNF is a critical cytokine in age-related dry eye disease. 30:119-128. 2023
Efficacy and safety of AZR-MD-001 selenium sulfide ophthalmic ointment in adults with meibomian gland dysfunction: A vehicle-controlled, randomized clinical trial. 29:537-546. 2023
TFOS Lifestyle: Impact of contact lenses on the ocular surface. 29:175-219. 2023
TFOS Lifestyle Report Introduction: A Lifestyle Epidemic - Ocular Surface Disease. 28:304-309. 2023
TFOS Lifestyle: Impact of societal challenges on the ocular surface. 28:165-199. 2023
Morphological characteristics of Meibomian Glands and their Influence on Dry Eye disease in contact lens wearers. 24:93-99. 2022
The impact of contact lenses on meibomian gland morphology. 24:148-155. 2022
Clinical practice patterns in the management of dry eye disease: A TFOS international survey. 21:78-86. 2021
Bibliometric analysis of the meibomian gland literature. 20:212-214. 2021
Developing evidence-based guidance for the treatment of dry eye disease with artificial tear supplements: A six-month multicentre, double-masked randomised controlled trial. 20:62-69. 2021
Cytomorphological assessment of the lid margin in relation to symptoms, contact lens wear and lid wiper epitheliopathy. 18:214-220. 2020
Geographic distribution of corneal staining in symptomatic dry eye. 18:258-266. 2020
Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: A systematic literature review. 17:412-423. 2019
TFOS DEWS II Report Executive Summary. 15:802-812. 2017
TFOS DEWS II Diagnostic Methodology report. 15:539-574. 2017
TFOS DEWS II Epidemiology Report. 15:334-365. 2017
TFOS DEWS II Introduction. 15:269-275. 2017
TFOS DEWS II Management and Therapy Report. 15:575-628. 2017
TFOS DEWS II Tear Film Report. 15:366-403. 2017
The University of Waterloo's Centre for Contact Lens Research. 9:242-244. 2011
Growth Factors in the Tear Film: Role in Tissue Maintenance, Wound Healing, and Ocular Pathology. 5:228-239. 2007
Association Between Corneal and Conjunctival Sensitivity, Tear Film Stability and Ocular Surface Appearance in Subjects with and without Dryness Symptoms. 3:S113-S113. 2005
Comparison of Non-Invasive Tear Break up Time and Bulbar Conjunctival Hyperemia in Postmenopausal Dry Eyed and Non-Dry Eyed Subjects. 3:S115-S115. 2005
Determination of Inferior Tear Meniscus Height and Inferior Tear Meniscus volume using Optical Coherence Tomography. 3:S76-S76. 2005
In-Situ Imaging of in Vitro Deposited Lysozyme and Albumin on Silicone Hydrogel and Hema Contact Lens Materials. 3:S119-S119. 2005
Measurement of Friction Associated with Lotrafilcon and Hema Hydrogel Contact Lenses. 3:S95-S95. 2005
Quantification and Conformational State of Lysozyme Deposition on Etafilcon, Balafilcon and Lotrafilcon Contact Lens Materials worn on a Daily Wear Basis. 3:S76-S76. 2005
Tear Meniscus Height is a Poor Predictor of Ocular Dryness Symptoms. 3:S62-S62. 2005

has subject area

1113 Opthalmology and Optometry (FoR)
Ophthalmology & Optometry (Science Metrix)